North American Report

Non-Cystic Fibrosis Bronchiectasis Pipeline Report 2021: Emerging Therapies and Key pharma players involved by DelveInsight | Novartis, InsMed, Zambon, Chiesi Farmaceutici and Many Others

 Breaking News
  • No posts were found

Non-Cystic Fibrosis Bronchiectasis Pipeline Report 2021: Emerging Therapies and Key pharma players involved by DelveInsight | Novartis, InsMed, Zambon, Chiesi Farmaceutici and Many Others

October 27
02:44 2021
Non-Cystic Fibrosis Bronchiectasis Pipeline Report 2021: Emerging Therapies and Key pharma players involved by DelveInsight | Novartis, InsMed, Zambon, Chiesi Farmaceutici and Many Others
Non-Cystic Fibrosis Bronchiectasis Pipeline

Non-cystic Fibrosis Bronchiectasis (henceforth referred to as bronchiectasis) is a progressive respiratory disease characterized by a permanent dilation of bronchi, retention of mucus, and ciliary clearance impairment. Clinical features include chronic daily sputum, cough, shortness of breath, and recurrent respiratory infections, with consequent increased morbidity and worsened quality of life. One of the cornerstones in the management of bronchiectasis is the identification and treatment of underlying causes.

 

DelveInsight’s Non-cystic Fibrosis Bronchiectasis Pipeline Insights report offers exhaustive coverage of the emerging therapies in different stages of development from pre-clinical till late-stage, along with dormant, inactive, and abandoned therapeutic agents. 

 

Some of the important takeaways from the Non-cystic Fibrosis Bronchiectasis Pipeline report:

  • NCFB Pipeline report offers an extensive analysis of 5+ key players and 5+ key therapies.
  • Non-cystic Fibrosis Bronchiectasis pipeline candidates are under evaluation in different stages of the clinical phase such as CHF 6333, Brensocatib, and others expected to get launched in the foreseeable future.
  • Some of the key companies expanding the Non-cystic Fibrosis Bronchiectasis Pipeline are Chiesi Farmaceutici, AstraZeneca, Insmed, among others.
  • In September, 2020, US biotech Insmed has trumpeted updated phase 2 data from its brensocatib, at this week’s virtual European Respiratory Society conference, showing the drug prolonged time to exacerbations caused by the rare lung disease known as non-cystic fibrosis bronchiectasis (NCFBE).

 

Request for free Sample Report: https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight

 

NCFB Symptoms

The symptoms and clinical course of NCFB are variable. Some patients have no symptoms at all or symptoms only during exacerbations, whereas others have them daily.

 

Non-cystic Fibrosis Bronchiectasis Causes

The most common cause of NCFB in the literature is post-infectious. This is not a well-defined entity, but the usual context appears to be one acute infectious episode that is thought to result in bronchiectasis. A possible mechanism for post-infectious NCFB is a significant infection in early childhood which causes structural damage to the developing lung, allowing perpetual bacterial infection. Over time, persistent infection may then result in bronchiectasis.

 

Non-cystic Fibrosis Bronchiectasis Companies are:

  • Santhera Pharmaceuticals
  • Novartis
  • InsMed
  • Zambon
  • Chiesi Farmaceutici
  • And Many Others

 

Request for free Sample Report: https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight

 

DelveInsight’s NCFB Report covers around 5+ products under different phases of clinical development like:

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Non-cystic Fibrosis Bronchiectasis Therapies are:

  • Lonodelestat
  • Tobramycin dry-powder inhalation
  • INS-1007
  • Colistimethate sodium
  • CHF 6333
  • And Many Others

 

 

Scope of the Non-Cystic Fibrosis Bronchiectasis Pipeline Report

Coverage: Global

Key Players: Santhera Pharmaceuticals, Novartis, InsMed, Zambon, Chiesi Farmaceutici, among others.

Key Non-Cystic Fibrosis Bronchiectasis Pipeline Therapies: Lonodelestat, Tobramycin dry-powder inhalation, INS-1007, Colistimethate sodium, CHF 6333, among others.

 

Table of Contents 

1

Report Introduction

2

Executive Summary

3

Non-Cystic Fibrosis Bronchiectasis Disease Overview

4

NCFB Pipeline Therapeutics Comparative Analysis

5

Non-Cystic Fibrosis Bronchiectasis Therapeutic Assessment

6

 Non-Cystic Fibrosis Bronchiectasis – DelveInsight’s Analytical Perspective

7

In-depth Commercial Non-Cystic Fibrosis Bronchiectasis Assessment

8

Non-Cystic Fibrosis Bronchiectasis Collaboration Deals 

9

Late Stage Non-Cystic Fibrosis Bronchiectasis Products (Phase III)

10

Mid-Stage Non-Cystic Fibrosis Bronchiectasis Products (Phase II)

11

Early Stage Non-Cystic Fibrosis Bronchiectasis Products (Phase I)

12

Pre-clinical and Discovery Stage NCFB Products

13

Inactive Non-Cystic Fibrosis Bronchiectasis Pipeline Products 

14

Key Non-Cystic Fibrosis Bronchiectasis Products

15

Unmet Needs

16

NCFB Market Drivers and Barriers

17

Future Perspectives and Conclusion

18

Analyst Views

19

Key Non-Cystic Fibrosis Bronchiectasis Companies

20

Appendix

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight